NAV

Doramectin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Doramectin
DrugBank Accession Number
DB11400
Background

Doramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle.

Type
Small Molecule
Groups
Vet approved
Structure
Similar Structures
Weight
Average: 899.128
Monoisotopic: 898.507857063
Chemical Formula
C50H74O14
Synonyms
  • Doramectin
  • Doramectina
  • Doramectine
  • Doramectinum
External IDs
  • L 701023
  • L-701023
  • UK 67994
  • UK-67,994
  • UK-67994
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Doramectin is combined with 1,2-Benzodiazepine.
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Doramectin.
AcalabrutinibThe serum concentration of Acalabrutinib can be increased when it is combined with Doramectin.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Doramectin.
AcetazolamideThe risk or severity of CNS depression can be increased when Acetazolamide is combined with Doramectin.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolides and analogues
Sub Class
Not Available
Direct Parent
Macrolides and analogues
Alternative Parents
Disaccharides / O-glycosyl compounds / Ketals / Oxanes / Pyrans / Tertiary alcohols / Tetrahydrofurans / Secondary alcohols / Lactones / Carboxylic acid esters
show 6 more
Substituents
Acetal / Alcohol / Aliphatic heteropolycyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Dialkyl ether / Disaccharide / Ether / Glycosyl compound
show 16 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
KGD7A54H5P
CAS number
117704-25-3
InChI Key
QLFZZSKTJWDQOS-YDBLARSUSA-N
InChI
InChI=1S/C50H74O14/c1-27-13-12-16-34-26-57-47-42(51)30(4)21-37(50(34,47)54)48(53)60-36-22-35(63-49(25-36)20-19-29(3)45(64-49)33-14-10-9-11-15-33)18-17-28(2)44(27)61-41-24-39(56-8)46(32(6)59-41)62-40-23-38(55-7)43(52)31(5)58-40/h12-13,16-17,19-21,27,29,31-33,35-47,51-52,54H,9-11,14-15,18,22-26H2,1-8H3/b13-12+,28-17+,34-16+/t27-,29-,31-,32-,35+,36-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47+,49+,50+/m0/s1
IUPAC Name
(1'R,2S,4'S,5S,6R,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-6-cyclohexyl-21',24'-dihydroxy-12'-{[(2R,4S,5S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-5,6-dihydro-3',7',19'-trioxaspiro[pyran-2,6'-tetracyclo[15.6.1.1^{4,8}.0^{20,24}]pentacosane]-10',14',16',22'-tetraen-2'-one
SMILES
[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(O4)O[C@H](C4CCCCC4)[C@@H](C)C=C5)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O

References

General References
  1. Authors unspecified: Doramectin--a novel avermectin. Vet Parasitol. 1993 Jul;49(1):1-119. [Article]
  2. Goudie AC, Evans NA, Gration KA, Bishop BF, Gibson SP, Holdom KS, Kaye B, Wicks SR, Lewis D, Weatherley AJ, et al.: Doramectin--a potent novel endectocide. Vet Parasitol. 1993 Jul;49(1):5-15. [Article]
  3. Yas-Natan E, Shamir M, Kleinbart S, Aroch I: Doramectin toxicity in a collie. Vet Rec. 2003 Dec 6;153(23):718-20. [Article]
  4. Stewart TB, Fox MC, Wiles SE: Doramectin efficacy against gastrointestinal nematodes in pigs. Vet Parasitol. 1996 Nov 1;66(1-2):101-8. [Article]
  5. Escudero E, Carceles CM, Diaz MS, Sutra JF, Galtier P, Alvinerie M: Pharmacokinetics of moxidectin and doramectin in goats. Res Vet Sci. 1999 Oct;67(2):177-81. [Article]
  6. Li N, Jiang H, Li J, Wang Z, Li C, Li X, Ding S: Pharmacokinetics of doramectin in rabbits after subcutaneous administration. J Vet Pharmacol Ther. 2009 Aug;32(4):397-9. doi: 10.1111/j.1365-2885.2008.01044.x. [Article]
  7. Atta AH, Abo-Shihada MN: Comparative pharmacokinetics of doramectin and ivermectin in sheep. J Vet Pharmacol Ther. 2000 Feb;23(1):49-52. [Article]
  8. Yazwinski TA, Tucker C, Featherston H, Johnson Z, Wood-Huels N: Endectocidal efficacies of doramectin in naturally parasitized pigs. Vet Parasitol. 1997 Jun;70(1-3):123-8. [Article]
  9. Ranjan S, Trudeau C, Prichard RK, Daigneault J, Rew RS: Nematode reinfection following treatment of cattle with doramectin and ivermectin. Vet Parasitol. 1997 Sep;72(1):25-31. [Article]
  10. Nentwig A, Oevermann A, Burgener IA: [Doramectin intoxication in 3 kittens]. Schweiz Arch Tierheilkd. 2014 Apr;156(4):179-83. doi: 10.1024/0036-7281/a000573. [Article]
ChemSpider
8008478
RxNav
73455
ChEMBL
CHEMBL2361641
ZINC
ZINC000245253793
Wikipedia
Doramectin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00599 mg/mLALOGPS
logP4.31ALOGPS
logP6.27Chemaxon
logS-5.2ALOGPS
pKa (Strongest Acidic)12.47Chemaxon
pKa (Strongest Basic)-3.4Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count13Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area170.06 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity238.58 m3·mol-1Chemaxon
Polarizability87.69 Å3Chemaxon
Number of Rings8Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0010010090-ffbeb579c26fb33e45bd
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-002e-0660011090-fa0ea414389b76da3d0e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03fs-0900010020-5cfc39c6235b2e65a7e3
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4m-0900013430-6c5738812c4452f741d8
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000t-2900002360-72f42516e8b51f9bcd7d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004j-1900001320-b9fe16a530bb9f76e3ac
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-307.1980696
predicted
DarkChem Lite v0.1.0
[M+H]+305.6628696
predicted
DarkChem Lite v0.1.0

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at February 25, 2016 18:25 / Updated at February 21, 2021 18:53